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Abstract: Cardiovascular disease (CVD) remains the leading cause of death in Western 
society today. There is a striking gender difference in CVD with men predisposed to earlier 
onset and more severe disease. Following the recent reevaluation and ongoing debate regard-
ing the estrogen protection hypothesis, and given that androgen use and abuse is increasing in 
our society, the alternate view that androgens may promote CVD in men is assuming increas-
ing importance. Whether androgens adversely affect CVD in either men or women remains a 
contentious issue within both the cardiovascular and endocrinological fraternities. This review 
draws from basic science, animal and clinical studies to outline our current understanding 
regarding androgen effects on atherosclerosis, the major CVD, and asks where future directions 
of atherosclerosis-related androgen research may lie.
Introduction
Epidemiological studies have shown there is a striking gender difference in cardio-
vascular disease (CVD) with men having higher rates of clinical events than women 
(Kalin and Zumoff 1999). These ﬁ  ndings, together with the increased incidence of 
CAD in women after menopause (Tracy 1966), have led to the dogma that female 
hormones protect against the development of CVD (Jeanes et al 2007). The opposite 
hypothesis, that male hormones may promote CVD in men, has been little inves-
tigated. With prospects of androgens being introduced widely for non-classical 
therapeutic applications, an important clinical question is: do androgens increase 
the risk or severity of CVD? Such androgen therapy is being targeted towards our 
aging population, a population that would have pre-existing CVD. The recent pro-
posal that stems from the female hormone replacement therapy (HRT) studies is that 
HRT appears beneﬁ  cial in females only when it is initiated before the development 
of signiﬁ  cant atherosclerosis (Rossouw et al 2007). Whether this is also true for 
androgen-based therapies is unknown. This review explores what is known about 
androgens and their gender-speciﬁ  c effects on the pathogenesis of atherosclerosis 
to try and highlight those questions that need to be answered for the safe use of 
androgen-based HRT in both men and women.
Risk factors of atherosclerosis
Primary risk factors for atherosclerosis include elevated levels of low-density lipo-
protein (LDL), increased levels of homocysteine, hypertension, diabetes mellitus, 
obesity, smoking, increasing age and also male gender (Ross 1999). In all developed 
countries, men have an earlier and greater incidence of heart disease than women (Liu 
et al 2003; Wu and von Eckardstein 2003; Isidori et al 2005). This may be one of the 
oldest clues to the underlying pathogenic mechanisms of atherosclerosis and suggests 
that gender-related differences between men and women drives, at least in part, the 
disparate atherosclerotic plaque formation (Liu et al 2003). There remains no clear Vascular Health and Risk Management 2008:4(1) 12
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evidence, to date, that there is a genetic contribution to the 
male predisposition to atherosclerosis, however the andro-
genic milieu may underlie plaque formation in men.
Molecular mechanisms of androgen 
action
The molecular machinery mediating cellular responses to 
androgens is complex and involves both genomic and nonge-
nomic effects that are still far from being clearly understood 
(Figure 1). Genomic effects of androgens are mediated by a 
speciﬁ  c receptor, the androgen receptor (AR). In response 
to the binding of androgens to AR, it switches to a transcrip-
tion factor that regulates target gene expression (Davison 
and Bell 2006). Non-genomic effects of androgens occur 
independently of AR. Instead, membrane-bound receptors
have been proposed to trigger rapid effects of androgens that 
lead to 2nd messenger signaling (Benton et al 2004). This, 
in turn, triggers a variety of cell responses (Wierman 2007). 
These nongenomic pathways underlie the rapid vasodila-
tion of coronary arteries by testosterone (Malkin et al 2006; 
Cooper et al 2007; Seyrek et al 2007).
Regulation and tissue expression
of AR
AR function and transactivation ability is regulated by post-
translational modiﬁ  cations such as phosphorylation (Zhou 
et al 1995; Gioeli et al 2002), acetylation and sumoylation 
(Thomas et al 2004). AR expression itself is regulated at both 
the mRNA and protein levels by androgens (Lee and Chang 
2002). Androgens predominantly decrease AR mRNA at 
Figure 1 Molecular mechanisms of androgen action. (1) Androgens mediate gene transcription via binding to the classical cytosolic AR in the genomic pathway; (2) Andro-
gens mediate rapid effects through a novel membrane receptor; (3) Androgens interact with the classical cytosolic AR associated with the plasma membrane; (4) Androgens 
act through a multi-protein complex associated with the plasma membrane.
Abbreviations: AR: androgen receptor; hsps: heat shock proteins;   ARE: androgen response element; mRNA: messenger RNA; mAR:putative membrane AR; cAMP: cyclic 
adenosine monophosphate; PKA: protein kinase A; ATP: adenosine triphosphate; CREB:cAMP response element binding protein; pCREB: phosphorylated CREB; PLC:phos-
pholipase C; PIP2: phosphatidyl inositol bisphosphate; DAG: diacylglycerol; IP3: inositol 3-phosphate; PKC: protein kinase C; ER: endoplasmic reticulum; SH2: Src homology 
domain; TK: tyrosine kinases; MEK: mitogen activated protein kinase-extracellular signal regulated kinase; ERK: extracellular signal regulated kinase; MAPK: mitogen-activated 
protein kinase.Vascular Health and Risk Management 2008:4(1) 13
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the transcriptional level (Trapman et al 1990; Krongrad et al 
1991) however, they simultaneously increase AR stability 
and translational efﬁ  ciency thereby even in the presence of 
decreased AR mRNA levels, androgens increase AR protein 
levels in most cell types (Yeap et al 1999).
AR has been detected in the majority of tissues throughout 
the body (Quigley et al 1995). AR is evident in vascular cells and 
gender-speciﬁ  c expression of AR has been shown in monocyte-
derived macrophages (Ng et al 2003), endothelial cells (Death 
et al 2004) and vascular tissue (Death et al 2004), where cells 
or tissue from male donors had signiﬁ  cantly higher AR protein 
levels. The gender dichotomy in AR expression may underlie 
gender-speciﬁ  c effects of androgens on atherosclerosis.
Metabolic activation of testosterone
Testosterone and other androgens can mediate effects via meta-
bolic activation (Figure 2). This involves the conversion of 
testosterone at peripheral nongonadal tissues to active metabo-
lites, estradiol or DHT. Conversion of testosterone to estradiol 
involves a P450-dependent aromatase enzyme (CYP19) and 
acts to diversify androgen action, since estradiol binds to the 
estrogen receptor (ER), and not AR, thereby regulating the 
expression of a completely different set of genes. The conver-
sion of testosterone to DHT is catalyzed by 5α-reductases. 
DHT has greater binding afﬁ  nity for AR than testosterone and 
a slower dissociation rate, therefore has a higher molar potency 
(Grino et al 1990). Hence, the conversion of testosterone to 
DHT effectively ampliﬁ  es AR action.
Androgens and vascular cell effects
Androgens have been shown to promote-, and suppress-, 
pro-atherogenic, pro-inﬂ  ammatory effects on all cell types 
involved in atherogenesis. Given current evidence it would 
appear that androgen effects are dependent on cell type, 
dose, type of androgen, and time of exposure. For example, 
T suppresses vascular cell adhesion molecule-1 (VCAM-1) 
expression in human endothelial cells, via an aromatase/
estrogen receptor-dependent mechanism (Hatakeyama et al 
2002; Mukherjee et al 2002); however, DHT, a non-aroma-
tisable androgen, induces VCAM-1 expression in human 
endothelial cells (Death et al 2004). Similarly, T has been 
shown to enhance reverse cholesterol transport (Langer et al 
2002) whilst DHT promotes cholesteryl ester accumula-
tion in monocyte derived macrophages (Ng et al 2003). In 
addition, T has been shown to inhibit nitric oxide release 
from monocytes via inhibition of inducible nitric oxide 
synthase (Friedl et al 2000). This decrease in NO potentially 
increases thrombosis risk via increased platelet aggregation. 
Additionally, T has adverse effects stimulating the prolif-
eration of rat vascular smooth muscle cells (Fujimoto et al 
1994), inducing proteoglycan synthesis and the elongation of 
glycosaminoglycans (GAG) chains on these proteoglycans 
(Hashimura et al 2005) and T increases apoptotic damage of 
vascular smooth muscle cells (Ling et al 2004). Importantly, 
some of the effects on both endothelial cells and MDMs 
were gender-speciﬁ  c, occurring in cells derived from males 
but not females, and associated with increased AR expres-
sion in male-derived cells (Ng et al 2003; Death et al 2004). 
This suggests that steps in atherogenesis could be markedly 
different between genders, mediated by androgen exposure 
and AR expression levels.
Therefore, both T and DHT can have effects that could 
lead to the development of atherosclerosis, associated with 
male-dependent AR expression. However, T can have equally 
anti-atherogenic effects, associated with aromatisation. Obvi-
ously, more work is required for us to understand how andro-
gens act at the cellular level. One of the major questions that 
has recently emerged is whether aromatisation is an important 
protective mechanism? There is now a real need to study and 
understand the metabolic activation pathways of T, in those 
cell types associated with atherosclerosis, and to determine 
if manipulating those pathways can switch between the ath-
eroprotective versus atherogenic effects of T?
Androgens and atherosclerosis: 
evidence from animal model studies
As with the cellular studies, androgen treatment has been 
shown to both promote and retard lesion formation in ani-
mal studies of atherosclerosis (Table 1). The effects of T 
appear to be gender-, steroid/dose/administration-, and/or 
species- speciﬁ  c. For the most part, T treatment of male 
animals has led to a decrease in atherosclerotic lesion size 
or the atherosclerosis-related end point studied (e.g. aortic 
cholesterol content) (Bruck et al 1997; Elhage et al 1997; 
Alexandersen et al 1999; Nathan et al 2001). Similarly, 
DHEA treatment of male animals has led to a decrease in 
atherosclerosis (Gordon et al 1988; Arad et al 1989; Eich 
et al 1993). Both T and DHEA are readily aromatisable to 
estradiol, and aromatase inhibition has been shown to block 
the atheroprotective effects of T (Nathan et al 2001). In 
keeping with the importance of aromatase to mediate the 
atheroprotective effects of T, a study showed that a 3-month 
treatment with an anabolic androgenic steroid, stanozolol, 
had no effect on atherosclerosis or blood lipids in choles-
terol-fed rabbits (Fogelberg et al 1990). Stanozolol is a 
5α-reduced substrate so it cannot be converted to estrogen Vascular Health and Risk Management 2008:4(1) 14
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by aromatase and therefore, only has androgenic effects. 
Interestingly, 2/10 stanozolol-treated normal diet fed rabbits 
developed atherosclerosis versus 0/72 control rabbits, thereby 
suggesting that stanozolol may increase the propensity for 
atherosclerotic lesion development. This was not followed 
up by these investigators.
In contrast to the studies that showed T was atheroprotec-
tive, two studies (out of 12) demonstrated increased athero-
sclerotic plaque formation after exogenous T treatment (Toda 
et al 1984; von Dehn et al 2001). However, both of these 
studies used an experimental approach that differed from 
usual practice. The ﬁ  rst studied chicks, rather than rodents, 
and they only observed increased atherosclerotic lesion when 
T was administered at 150 mg for 7 weeks (compared to 50 
mg/day/rabbit for 3 months, Bruck et al 1997). No studies 
have subsequently been performed in chicks to conﬁ  rm the 
original ﬁ  ndings. The second study demonstrating adverse 
effects of T used chemical, rather than surgical, castration 
of apoE-deﬁ  cient mice. In this model, T treatment (35 mg 
dosage) was observed to increase atherosclerotic lesion area 
by a signiﬁ  cant, but small, extent. This study did not examine 
the aromatase pathway so in this animal model it is not clear 
Figure 2 Schematic representation of the major sources of androgens in men and women. (MEN) The hypothalamic-pituitary-gonadal axis in men. The dotted lines repre-
sent the pulsatile release of gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH) and luteinising hormone (LH). LH serves to stimulate the testis to 
produce testosterone (T) or FSH stimulates production of inhibin. In turn, these exert a negative feedback on both the pituitary and hypothalamus regulating LH and FSH 
secretion. T can be reduced to the more active dihydrotestosterone (DHT) or aromatised to estradiol (E2) in target tissues. (WOMEN) The hypothalamic-pituitary-ovarian 
and hypothalamic-pituitary-adrenal axis represents the major sources for androgen synthesis in women. In addition to inhibin and cortisol, high levels of E2, progesterone 
(P) and adrenal androgens exert a negative feedback to regulate the secretions of GnRH, corticotropin-releasing hormone (CRH), FSH, LH and adrenocorticotropic hor-
mone (ACTH).Vascular Health and Risk Management 2008:4(1) 15
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if aromatase would be expressed, which could help explain 
the disparate result.
As with the male animal model data, testosterone effects 
on atherosclerotic plaque formation in female animal models 
is also contentious. The data that exists is very limited with 
only 5 studies in total. Three of these studies were performed 
in rodents and testosterone was found to decrease lesion size 
in 2/3 of them (Elhage et al 1997; von Dehn et al 2001). The 
third rodent study showed no effect of testosterone treat-
ment on atherosclerotic plaque development (Chen et al 
1996). The other two female animal studies were performed 
with primates and showed that testosterone or the anabolic 
androgen, nandrolone, induced atherosclerosis over a 2-year 
treatment period (Adams et al 1995; Obasanjo et al 1996). 
These primate studies, whilst only have a small number of 
animals in the experimental groups, remains the strongest 
evidence that exogenous androgen treatment may be ath-
erogenic in females.
Importantly, all of the animal studies have targeted the 
effects of androgens on atherosclerotic plaque development 
without examining an effect of T on existing plaque. As has 
now been highlighted by the recent estrogen therapy trials, 
the timing of hormone therapies can have different outcomes 
on CVD. Although contentious, and remains to be proven, 
estrogen-based therapies given after plaque has developed 
leads to adverse effects (increased myocardial infarction, 
stroke) in the short-term. Whether androgen-based therapies 
have similar outcomes dependent on timing and age of patient 
has not been investigated.
Figure 3 summarizes the primary effect of androgen and 
estrogen treatment on atherosclerotic lesion development, as 
measured in animal studies. Note that many more studies have 
targeted estradiol effects and the number of androgen studies 
are relatively small in comparison, especially those that focus 
on T effects in females. Therefore, it remains unclear whether 
T is anti- or pro-atherogenic in female animal models, whilst 
in males T is atheroprotective, most probably via aromatisa-
tion to estradiol. Direct T or stanozolol effects appear to be 
atherogenic, although the limited number of studies do not 
allow for any ﬁ  rm conclusions to be made. Therefore, andro-
gens, atherosclerosis, and gender-speciﬁ  c effects remains an 
important area for future research development.
Androgens and atherosclerosis: 
evidence from clinical studies
To date, the major clue that androgens may drive CAD in 
men remains the gender dichotomy in the earlier incidence 
of atherosclerosis. However, epidemiologic studies report no 
association between high physiologic androgen levels and 
atherosclerosis (English et al 2000; Hak et al 2002; Muller 
et al 2004). Instead, the inverse has been reported namely 
that hypoandrogenemia associates with CAD (Malkin 
et al 2003), or an atherogenic lipid proﬁ  le (Tchernof et al 
1997; Zmuda et al 1997), metabolic syndrome (Kupelian 
et al 2006), type 2 diabetes (Haffner et al 1996; Stellato 
et al 2000), systolic and diastolic hypertension (Svartberg 
et al 2004), visceral obesity (Khaw and Barrett-Connor 
1992), increased ﬁ  brinogen (Bonithon-Kopp et al 1988), 
arterial stiffness (Hougaku et al 2006) and all-cause or 
cardiovascular deaths (Barrett-Connor and Khaw 1988). 
Hypoandrogenemia is common and it has been reported 
that 10% of men between 40 and 60 years of age and 25% 
between 60 and 80 years of age have low levels of free T 
(Vermeulen and Kaufman 2002) therefore hypo- rather than 
hyper- androgenemia may be the gender-speciﬁ  c factor driv-
ing atherosclerosis. However, not all studies have found an 
association between hypoandrogenemia and increased CVD 
(Contoreggi et al 1990) therefore it is difﬁ  cult to draw any 
ﬁ  rm conclusions. It is of interest that castration of male 
rodents has been shown to increase atherosclerosis in animal 
models of atherosclerosis (Nathan et al 2001).
Given that low T levels appear harmful for CVD and 
its important risk factors, T supplementation would be 
expected to be beneﬁ  cial. Meta-analysis review of car-
diovascular safety of T replacement therapy has reported 
that T supplementation was relatively safe in terms of 
cardiovascular health (Haddad et al 2007). However, this 
meta-analysis needs to be interpreted with caution as none 
of the randomized controlled trials that were included in the 
analysis were designed to assess cardiovascular safety and 
therefore adverse outcomes may have been censored and/or 
not reported, therefore, weakening the meta-analysis conclu-
sions. However, other studies have shown that T replacement 
therapy has demonstrable beneﬁ  cial effects on CVD risk 
factors, including waist measurements (Marin et al 1992), 
visceral abdominal fat mass (Marin et al 1992), as well as 
positive effects on numerous metabolic parameters includ-
ing insulin sensitivity, glucose control, and hyperlipidemia 
(English et al 2000; Malkin et al 2006). Direct effects on 
the arterial tree have also been described with consistent 
improvement in both anginal symptoms and ischemia on 
electrocardiograms in men treated with injectable T prepa-
rations (Rosano et al 1990; Webb et al 1999; English et al 
2000; Pugh et al 2003).
However, while the observations above would suggest T 
supplementation improves CVD risk factors, meta-analysis Vascular Health and Risk Management 2008:4(1) 17
Androgen therapy and atherosclerotic cardiovascular disease
by Whitsel et al (2001) found a dose-dependent decrease in 
HDL-C and total cholesterol levels with T use in hypogondal 
men. Similarly, small intervention trials have demonstrated 
that exogenous T supplementation in young men lowers HDL 
(Meriggiola et al 1995; Wu et al 1996) but in older men T 
did not affect HDL (Snyder et al 2001; Page et al 2005). The 
disparite ﬁ  ndings may indicate that the effect of T replace-
ment on HDL may be age-dependent. Any effect of T on 
lowering HDL-C needs to be considered as low HDL levels 
are a strong risk factor for CVD (Gordon et al 1997).
Other cardiovascular diseases that often coexist with 
CVD, including hypertension and ischemic stroke, also show 
a similar gender bias, with males at higher risk. Androgens 
have been reported to adversely affect both conditions, 
with reports of prohypertensive effects (Jenkins et al 1994; 
Reckelhoff 2005) and to worsen the acute phase of stroke 
(Hawk et al 1998). Therefore, when considering T replace-
ment therapy in aging men, the effect on atherosclerosis 
cannot be considered without simultaneously investigating 
hypertension and stroke (Figure 4).
Anabolic androgenic steroid (AAS) use has been anec-
dotally associated with various forms of cardiovascular 
disease. Self-administration of AAS has been linked with 
sudden cardiac death, androgen-induced vasospasm, platelet 
Figure 3 Animal model studies examining the effects of androgens on atherosclerosis. Total number of animal model studies are represented by the solid grey bar. Of the 
total number of studies, male studies are represented by the black solid bar. Of the total number of studies, female studies are represented by the hatched bar. T=pro-
atherogenic – represents the number of animal model studies showing pro-atherogenic effects of   T treatment or castration;   T=protective/null – represents the number 
of animal model studies showing protective or null effects of   T treatment or castration; E2=pro-atherogenic – represents the number of animal model studies showing 
pro-atherogenic effects of   T treatment or castration; E2=protective/null – represents the number of animal studies showing protective or neutral effects of T treatment or 
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aggregation, activation of the coagulation cascade, and 
abnormal left ventricular function and hypertrophy (Maron 
et al 1996). It has also been reported that self-administration 
of several AAS simultaneously for 8 or 14 weeks produces 
profound unfavorable effects on lipoproteins and lipids, 
leading to an increased atherogenic proﬁ  le (Hartgens et al 
2004). However, any link between the adverse lipid proﬁ  le 
induced by AAS use and increased atherosclerosis remains 
to be established.
In women, it is much clearer that androgen excess is 
linked to the burden of CVD risk factors. The most well 
studied of such risk factors is insulin resistance. It has been 
hypothesized that insulin resistance is a consequence of 
androgen effects. Excessive androgenic steroid exposure of 
female rats (Holmang et al 1990), normal females (Polder-
man et al 1994), transsexual females (Bjorntorp 1993), and 
patients with aplastic anemia (Woodard et al 1981) can lead 
to insulin resistance and may at least be partly reversed by 
estrogen administration (Andersson et al 1997). In keeping 
with this hypothesis, it was recently demonstrated that post-
menopausal women with well-controlled type 2 diabetes 
that are insulin resistant show evidence of biochemical and 
clinical androgen excess, compared to non-diabetic, post-
menopausal women with no known risk factors for diabetes 
other than obesity (Korytkowski et al 2005). Further evidence 
of a link between high androgen levels and CVD or CVD 
risk factors is observed in women with polycystic ovary 
syndrome (PCOS). Women with PCOS have a sustained 
exposure to high physiologic androgen levels. This condition 
is associated with endothelial dysfunction, obesity and meta-
bolic abnormalities such as insulin resistance and dyslipidae-
mia, all of which may predispose PCOS women to premature 
atherosclerosis (Paradisi et al 2001; Krentz et al 2007).
However, despite the association between excess andro-
gen in women and insulin resistance, CVD risk factors and 
angiographical evidence of atherosclerosis, there remains 
no evidence of increase cardiovascular mortality in these 
women. Additionally, in female-to-male transsexuals, testos-
terone therapy has not been linked to excess cardiovascular 
mortality or morbidity (van Kesteren et al 1997). Therefore, 
the question of the cardiovascular safety of androgen therapy 
in women remains unanswered. Based on existing observa-
tions, androgen use may increase insulin resistance in women 
with a consequent sequalae of cardiovascular effects however 
apart from the observations in women with PCOS and type 
2 diabetes, and animal data suggesting androgens promote 
atherosclerosis in females, there is no solid data to support 
the claim (Figure 4). More work is necessary to establish a 
real link between androgens, insulin resistance and athero-
sclerosis in women.
Summary
From our current understanding of the effects of androgens 
on atherosclerosis, it has become apparent that the view 
androgens are harmful is too simplistic. This is made most 
evident by the erratic nature of the ﬁ  ndings reported in cel-
lular, animal and clinical studies. Clearly, much more work 
is needed in both the basic science and clinical arenas to 
Figure 4 Summary of the effects of exogenous T treatment on cardiovascular endpoints.Vascular Health and Risk Management 2008:4(1) 19
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fully elucidate the effects of androgens on the development 
of atherosclerosis. For men, exogenous T treatment appears 
largely beneﬁ  cial, at least in part via aromatization of T to 
estradiol, especially if physiological T levels are deﬁ  cient. 
However, self-administered AAS usage remains a major 
CVD safety concern, especially given reported adverse 
lipid proﬁ  le effects. As clinicians consider the use of T in 
management of symptoms associated with the aging male, 
there remains inconsistent and poorly reported data on car-
diovascular risk of long-term T use. For T treatment in aging 
women, the current data would suggest androgen excess has 
adverse effects on CVD risk factors, especially in women 
with diabetes. In summary, there remains limited knowledge 
about exogenous androgen treatments in both men and 
women. Despite this, androgen use and abuse is increasing 
in our society, either for therapeutic or recreational reasons. 
Whether androgens adversely affect CVD in either men or 
women remains a contentious issue that is in desperate need 
of more research.
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